Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Siponimod

FDA-approved product (tablet, oral), marketed as Mayzent, Siponimod.

Registered studies
33
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Siponimod
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Multiple sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sphingosine-1-phosphate (s1p) receptor modulators
FDA pharmacologic class
Sphingosine 1-phosphate Receptor Modulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Siponimod in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Siponimod with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Repurposing Siponimod for Alzheimer's Disease

    NCT06639282 · start 2025-08-26

    Registered record
    Registry ID
    NCT06639282
    Conditions
    Alzheimer Disease; Mild Alzheimer Disease; MCI With Increased Risk for Alzheimer Disease; Cognitive Impairment, Mild
    Interventions
    Siponimod; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-26
    Completion
    2029-10
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Mild Alzheimer Disease; MCI With Increased Risk for Alzheimer Disease; Cognitive Impairment, Mild
    InterventionSiponimod; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia

    NCT07168694 · start 2024-04-16

    Registered record
    Registry ID
    NCT07168694
    Conditions
    Secondary Progressive Multiple Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-04-16
    Completion
    2024-09-26
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

    NCT06395909 · start 2023-04-23

    Registered record
    Registry ID
    NCT06395909
    Conditions
    Relapsing Multiple Sclerosis; Clinically Isolated Syndrome; Relapsing Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-23
    Completion
    2023-08-31
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing Multiple Sclerosis; Clinically Isolated Syndrome; Relapsing Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis

    NCT06588387 · start 2022-11-03

    Registered record
    Registry ID
    NCT06588387
    Conditions
    Secondary Progressive Multiple Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-11-03
    Completion
    2023-09-08
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

    NCT05376579 · start 2022-06-17

    Registered record
    Registry ID
    NCT05376579
    Conditions
    Active Secondary Progressive Multiple Sclerosis
    Interventions
    siponimod
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-17
    Completion
    2025-07-22
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Secondary Progressive Multiple Sclerosis
    Interventionsiponimod
    PhaseNot recorded
    Registry statusCompleted

  • Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

    NCT04933552 · start 2021-12-15

    Registered record
    Registry ID
    NCT04933552
    Conditions
    Multiple Sclerosis
    Interventions
    Siponimod
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-12-15
    Completion
    2032-05-31
    Enrolment
    867

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionSiponimod
    PhaseNot recorded
    Registry statusRecruiting

  • Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials

    NCT05301907 · start 2021-12-02

    Registered record
    Registry ID
    NCT05301907
    Conditions
    Multiple Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-02
    Completion
    2025-05-16
    Enrolment
    335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

    NCT04895202 · start 2021-11-19

    Registered record
    Registry ID
    NCT04895202
    Conditions
    Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
    Interventions
    Siponimod
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-11-19
    Completion
    2022-12-20
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
    InterventionSiponimod
    PhaseNot recorded
    Registry statusTerminated

  • Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

    NCT04925557 · start 2021-11-13

    Registered record
    Registry ID
    NCT04925557
    Conditions
    Secondary-progressive Multiple Sclerosis
    Interventions
    Mayzent; Ocrevus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2021-11-13
    Completion
    2023-08-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary-progressive Multiple Sclerosis
    InterventionMayzent; Ocrevus
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

    NCT04926818 · start 2021-10-05

    Registered record
    Registry ID
    NCT04926818
    Conditions
    Multiple Sclerosis (MS)
    Interventions
    Fingolimod; Ofatumumab; Siponimod; Fingolimod placebo; Siponimod placebo; Ofatumumab placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-10-05
    Completion
    2031-02-28
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis (MS)
    InterventionFingolimod; Ofatumumab; Siponimod; Fingolimod placebo +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

    NCT05688436 · start 2021-09-24

    Registered record
    Registry ID
    NCT05688436
    Conditions
    Multiple Sclerosis
    Interventions
    Diroximel Fumarate; Alemtuzumab; Fingolimod; Glatiramer acetate; Interferon beta; Natalizumab; Ocrelizumab; Ofatumumab; Ozanimod; Peginterferon beta-1a; Ponesimod; Siponimod
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-09-24
    Completion
    2031-01-17
    Enrolment
    1,178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionDiroximel Fumarate; Alemtuzumab; Fingolimod; Glatiramer acetate +8 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • COVID-19 Vaccine Response in Treated MS Patients

    NCT05060354 · start 2021-06-01

    Registered record
    Registry ID
    NCT05060354
    Conditions
    Multiple Sclerosis; Healthy
    Interventions
    Blood draw
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-06-01
    Completion
    2023-09-28
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Healthy
    InterventionBlood draw
    PhaseNot recorded
    Registry statusCompleted

  • Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

    NCT04792567 · start 2021-04-19

    Registered record
    Registry ID
    NCT04792567
    Conditions
    Secondary Progressive Multiple Sclerosis
    Interventions
    BAF312; Baseline disease modifying therapies (DMTs); BNT162; mRNA-1273
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-19
    Completion
    2022-08-15
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis
    InterventionBAF312; Baseline disease modifying therapies (DMTs); BNT162; mRNA-1273
    PhasePhase 4
    Registry statusCompleted

  • Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

    NCT05576779 · start 2020-12-03

    Registered record
    Registry ID
    NCT05576779
    Conditions
    Multiple Sclerosis
    Interventions
    Ofatunumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-03
    Completion
    2021-12-31
    Enrolment
    2,101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionOfatunumab
    PhaseNot recorded
    Registry statusCompleted

  • Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies

    NCT06459232 · start 2020-11-19

    Registered record
    Registry ID
    NCT06459232
    Conditions
    Multiple Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-19
    Completion
    2021-12-17
    Enrolment
    143

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted